Статья
ФИБРИЛЛЯЦИЯ ПРЕДСЕРДИЙ И ТИРЕОТОКСИКОЗ
Излагаются современные представления о функциях щитовидной железы, их лабораторной оценке, диагностике и лечении гипо- и гипертиреоза, в том числе развившегося на фоне терапии амиодароном.
1. Берестенникова Л.Н., Чумакова Г.А., Тимофеев А.В. Влияние тироксина на течение мерцательной аритмии у больных без тиреотоксикоза. Актуальные вопросы медицины: сборник научных работ / МУЗ «Городская больница № 1». Барнаул, 2007, с.67-68.
2. Быстрова Т.В., Трошина Е.А., Абдулхабирова Ф.М. Состояние сердечно-сосудистой системы при субклиническом тиреотоксикозе. Болезни сердца и сосудов. 2006, 1 (3), с.51-53.
3. Герасимов Г.А., Фадеев В.В., Свириденко Н.Ю., Мельниченко Г.А., Дедов И.И. Йододефицитные заболевания в России. Простое решение сложной проблемы. М.; Адаманть, 2002.- 168 с.
4. Гратий К.Ф., Гроссу А.А., Кузор Т.С., Ченуша О.В. Особенности мерцательной аритмии у пациентов с гиперфункцией щитовидной железы. Кардиоваскулярная терапия и профилактика. 2008, 7(6), Приложение 1, с.98.
5. Диагностика и лечение фибрилляции предсердий. Российские рекомендации. Приложение к журналу «Кардиоваскулярная терапия и профилактика». 2005. - 28 с.
6. Клинические рекомендации. Эндокринология / под ред. И.И. Дедова, Г.А. Мельниченко. - М. : ГЭОТАР-Медиа, 2007. - 304 с.
7. Миллер О.Н., Скурихина О.Н., Старичков С.А. Применение препаратов IC класса у больных с фибрилляцией предсердий на фоне артериальной гипертонии и хронической сердечной недостаточности с сохраненной систолической функцией. Российский кардиологический журнал. 2008, 4 (72).
8. Радзевич А.Э., Коняхин А.Ю., Каменева Т.Р. и др. Место этацизина в терапии фибрилляции предсердий. Кардиолог. 2005, №1, с.1-7.
9. Свириденко Н.Ю., Платонова Н.М., Молашенко Н.В. Нарушения функции щитовидной железы при приеме амиодарона. Проблемы эндокринологии. 2002, т.48, №2, с.22-27.
10. Свириденко Н.Ю., Платонова Н.М., Молашенко Н.В. и др. Состояния, вызванные приемом амиодарона, в практике кардиолога и эндокринолога. Лечащий врач. 2004, №2, с.16-20.
11. Сердюк С.Е., Бакалов С.А., Голицын С.П. и др. Дисфункция щитовидной железы на фоне длительного приема амиодарона. Связь антиаритмической эффективности амиодарона с действием препарата на функцию щитовидной железы. Кардиология. 2005, № 1, с.22-27.
12. Тавровская Т.В., Шатилло К.Г., Лих Н.А. и др. Впервые выявленная мерцательная аритмия: характеристика пациентов. Кардиоваскулярная терапия и профилактика. 2007, 6 (5), Приложение 1, с. 299.
13. Уитман Э. Этиология, диагностика и лечение болезни Грейвса // Thyroid Intemational.-2003, №2, с.3-15.
14. Фадеев В.В., Мельниченко Г.А. Гипотиреоз (руководство для врачей). - М., «РКИ Северо пресс», 2002.
15. Фадеев В.В. Диагностика и лечение токсического зоба. Русский медицинский журнал. 2002, том 10, № 11 (155), с. 513 - 516.
16. Фадеев В.В. Болезнь Грейвса. Русский медицинский журнал. 2002, том 10, № 27 (171) - С.1262-1265.
17. Фадеев В.В. Узловые образования щитовидной железы: международные алгоритмы и отечественная клиническая практика. Врач. 2002, №7, с.12-16.
18. Фадеев В.В. Патогенетическая терапия эутиреоидного зоба. Consilium medicum. 2002. Том 4. № 10, с.516-520.
19. Фадеев В.В. Нормативы уровня ТТГ: нужны ли изменения? Клиническое эссе. Клиническая тиреоидология.2004, №3, с.5-9.
20. Чазов Е.И., Дедов И.И., Голицын С.П. и др. Кардиальные и эндокринные аспекты применения амиодарона в современной практике лечения нарушений ритма сердца. Москва.2005.-56 с.
21. Чумакова Г.А., Берестенникова Л.Н., Тимофеев А.В. и др. Распространенность дисфункций щитовидной железы среди пациентов с мерцательной аритмией. Кардиоваскулярная терапия и профилактика, 2006, 5; 6 (приложение), с.418-419.
22. Шилин Д.Е. Актуальные вопросы лабораторной диагностики заболеваний щитовидной железы (современные рекомендации международных организаций). Лаборатория. 2002, № 3, с. 22-26.
23. Эндокринология. Под ред. Н. Лавина. Пер с англ. - М.: Практика, 1999. - 1128 с.
24. AACE/AME medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. Endocr Pract 2006; 12(1): 67-102.
25. Agner T., Almdal T., Thorsteinsson B., Agner E. A reevaluation of atrial fibrillation in thyrotoxicosis. Dan Med Bull 1984; 31: 157-159.
26. Asvold et al. Thyrotropin Levels and Risk of Fatal Coronary Heart Disease: The HUNT Study. Arch Intern Med. 2008; 168(8): 855-860.
27. ATA Statement on «Wilson’s Syndrome» updated May 24, 2005.American Thyroid Association. http: //www.thy-roid.org/professionals/publications/statements/99_11_16_ wilsons.html
28. Aras D., Maden O., Ozdemir O., et al. Simple electrocardiographic markers for the prediction of paroxysmal atrial fibrillation in hyperthyroidism. Int J Cardiol 2005; 99(1): 59-64.
29. Auer J.A., Scheibner P., Mische T., et al. Subclinical hyperthyroidism as a risk factor for atrial fibrillation. American Heart Journal 2001; 142: 838-842
30. Balzano S., Sau F., Bartalena L., et al. Diagnosis of amiodarone-iodineinduced thyrotoxicosis (AIIT) associated with severe nonthyroidal illness. J Endocrinol Invest 1987; 10: 589-591.
31. Basaria S., Cooper D.S. Amiodarone and the thyroid. Am J Med 2005; 118 (7): 706-714.
32. Baskin H.J., et al. American association of clinical endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract 2002; 8: 457-469.
33. Bernstein R., Miller C., Midtbo K., et al. Silent myocardial ischemia in hypothyroidism. Tyroid 1995; 5: 443-447.
34. Bindi M., Pinelli M., Rosada J., Castiglioni M. Atrial fibrillation and thyroid gland. Recenti Prog Med 2005; 96(11): 548-551.
35. Biondi B., Palmieri E.A., Lombardi G., Fazio S. Effects of subclinical thyroid dysfunction on the heart. Ann Intern Med 2002; 137: 904-914.
36. Biondi B., Palmieri E.A., Klain M., et al. Subclinical hyperthyroidism: clinical features and treatment options. European Journal of Endocrinology. 2005; 152: 1-9.
37. Biondi B., Cooper D.S. The Clinical Significance of Subclinical Thyroid Dysfunction. Endocr Rev 2008; 29: 76-131.
38. Boelaert K., Franklyn J.A. Thyroid hormone in health and disease. Journal of Endocrinology. 2005; 187: 1-15.
39. Bogazzi F., Bartalena L., Gasperi M., et al. The various effects of amiodarone on thyroid function. Thyroid 2001; 11: 511-519.
40. Bogazzi F. Amiodarone and thyroid hormone metabolism. Hot thyroidology 2003; 2 (www.hotthyroidology.com).
41. Bonnema S.J., Bennedbæk F.N., Wiersinga W.M., Hegedüs L. Management of the nontoxic multinodular goitre: a European questionnaire study. Clin Endocrinol (Oxf) 2000; 53: 5-12.
42. Bonnema S.J., Bennedbæk F.N., Ladenson P.W., Hegedüs L. Management of the nontoxic multinodular goiter: a North American survey. J Clin Endocrinol Metab 2002; 87: 112-117.
43. Braunwald's heart disease: a textbook of cardiovascular medicine / edited by D.P. Zipes et al. - 7-th ed. - Philadelphia, 2005.
44. Cappolo A.R., Ladenson P.W. Hypothyroidism and atherosclerosis. J Clin Endocrinol Metab 2003; 88: 2438-2444.
45. Cardenas G.A., Cabral J.M., Leslie C.A. Amiodarone-induced thyrotoxicosis: diagnostic and therapeutic strategies. Cleveland Clinic Journal of Medicine 2003; 70(7): 624-631.
46. Chiacchieri M., Cecchi F., Arcangeli C., et al. Occult thyrotoxicosis in patients with chronic and paroxysmal isolated atrial fibrillation. Clinical Cardiology 1984; 7: 413-416.
47. Chiovato L., Mariotti S., Pinchera A. Thyroid diseases in the elderly. Baillieres Clin Endocrinol Metab 1997; 11(2): 251-70.
48. Chuo A.M., Lim J.K. Thyroid dysfunction in elderly patients. Ann Acad Med Singapore 2003; 32(1): 96-100.
49. Cooper D.S., et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006; 16(2): 1-33.
50. Cooper D.S. Approach to the Patient: Subclinical Hyperthyroidism. J Clin Endocrinol Metab. 2007; 92(1): 3-9.
51. Danias P.G., Coulfield T.A., Weigner M.J., et al. Likelihood of spontaneous conversion of atrial fibrillation to sinus rhythm. J Am Coll Cardiol 1998; 31: 588-592.
52. Davidson E., Weinberger I., Rotenberg Z., et al. Atrial fibrillation. Cause and time of onset. Arch Intern Med 1989; 149: 457-9.
53. Demers L.M., Spencer C.A. National Academy of Clinical Biochemistry (NACB). NACB: laboratory support for the diagnosis and monitoring of thyroid disease. Washington (DC): National Academy of Clinical Biochemistry (NACB); 2002.-125 p.
54. Dickstein G., Shechner C., Adawi F., et al. Lithium treatment in amiodarone-induced thyrotoxicosis. Am J Med.1997; 102: 454-458.
55. Eaton S.E., Euinton H.A., Newman C.M., et al. Clinical experience of amiodarone induced thyrotoxicosis over a 3-year period: role of colour-flow Doppler sonography. Clin Endocrinol 2002; 56: 33-38.
56. Fadel B.M., Ellahham S., Ringel M.D., et al. Hyperthyroid Heart Disease. Clin. Cardiol. 2000; 23, 402-408.
57. Feldkamp J., Seppel T., Becker A., et al. Iodide or l-thyroxine to prevent recurrent goiter in an iodine-deficient area: prospective sonographic study. World J Surg 1997; 21: 10-14.
58. Fierro N., Gonnella C., Pietropaolo L., et al. Atrial fibrillation and hyperthyroidism: results after thyroidectomy. G Chir 2002; 23(11-12): 431-3.
59. Fisher J.N. Management of thyrotoxicosis.South Med J 2002; 95(5): 493-505.
60. Forfar J.C., Miller H.C., Toft A.D. Occult thyrotoxicosis: a reversible cause of “idiopathic” atrial fibrillation. Am J Cardiol 1979; 44: 9-12.
61. Forfar J.C., Feek C.M., Miller H.C., Toft A.D. Atrial fibrillation and isolated suppression of the pituitary thyroid axis. Response to specific antithyroid therapy. International Journal of Cardiology 1981; 1: 43-48.
62. Franklyn J., Maisonneuve P., Sheppard M., et al. Mortality after treatment of hyperthyroidism with radioactive iodine. N Engl J Med. 1998; 338: 712-718.
63. Frost L., Vestergaard P., Mosekilde L. Hyperthyroidism and Risk of AtrialFib rillation or Flutter -A Population-Based Study. Arch Intern Med 2004; 164: 1675-1678.
64. Fuster V., Rydén L.E., Cannom D.S. et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). European Heart Journal 2006; 27: 1979-2030.
65. Hamburger J.I. Evolution of toxicity in solitary nontoxic autonomously functioning thyroid nodules. J Clin Endocrinol Metab 1980; 50: 1089-1093.
66. Hamilton M.A., Stevenson L.W., Fonarow G.C., et al. Safety and hemodynamic effects of intra-venous triiodothyronine in advanced congestive heart failure. Am J Cardiol 1998; 81: 443-7.
67. Hammer J., Johanningmann K., Schatz H., Pfeilschifter J. Subclinical hyperthyroidism is an independent risk factor for atrial fibrillation in patients with preexisting cardiac disease. Experimental and Clinical Endocrinology and Diabetes 2001; 109: S37.
68. Hedberg C.W., Fishbein D.B., Janssen R.S., et al. An outbreak of thyrotoxicosis caused by the consumption of bovine thyroid gland in ground beef. N Engl J Med 1987; 316: 993-998.
69. Hegedus L., Bonnema S.J., Bennedbaek F.N. Management of simple nodular goiter: current status and future perspectives. Endocr Rev 2003; 24: 102-132.
70. Gharib H., Goellner J.R. Fine-needle aspiration biopsy of the thyroid: an appraisal. Ann Intern Med 1993; 118: 282-289.
71. Goldman M.B., Maloof F., Monson R.R., et al. Radioactive iodine therapy and breast cancer. A follow-up study of hyperthyroid women. Am J Epidemiol 1988; 127: 969-980.
72. Gussekloo J., van Exel E., de Craen A.J.M., et al. Thyroid Status, Disability and Cognitive Function, and Survival in Old Age. JAMA 2004; 292(21): 2591-2599.
73. Iervasi G., Pingitore A,. Landy P., et al. Low T3-sin-drome: A strong prognostic predictor of death in patients with heart disease. Circulation 2003; 107: 708.
74. Jayaprasad N., Johnson Francis. Atrial Fibrillation and Hyperthyroidism. Indian Pacing and Electrophysiology Journal 2005; 5(4): 305-311.
75. Joseph K. Funktionelle Autonomie und jodinduzierte Hyperthyreose: Jodmedikation und Hyperthyreose. Akt Endokr 1992; 13: 102-108.
76. Kahaly G.J., Dillmann W.H. Thyroid Hormone Action in the Heart. Endocrine Reviews 2005; 26(5): 704-728.
77. Klein I., Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 2001; 344: 501-509.
78. Klemperer J.D., Klein I., Gomez M., et al. Thyroid hormone treatment after coronary-artery bypass surgery. N Engl J Med 1995; 333: 1522.
79. Koutras D. Subclinical hyperthyroidism. Thyroid 1999; 9: 311-315.
80. Krahn A.D., Klein G.J., Kerr C.R., et al. How useful is thyroid function testing in patients with recent-onset atrial fibrillation? Arch Intern Med 1996; 156: 2221-4.
81. Loh K.C. Amiodarone-induced thyroid disorders: a clinical review. Postgrad Med J 2000; 76: 133-140.
82. Lu X.Z., Huang J., Zhang X.W., et al. Effects of thyroxine on cardiac function and lymphocyte ß-adrenoceptors in patients with chronic congestive heart failure. Chinese Medical Journal 2003; 116(11): 1697-1700.
83. Martino E., Safran M., Aghini-Lombardi F., et al. Environmental iodine intake and thyroid dysfunction during chronic amiodarone therapy. Ann Intern Med 1984; 101: 28-34.
84. Martino E., Bartalena L., Bogazzi F., et al. The effects of amiodarone on the thyroid. Endocr Rev. 2001; 22: 240-254.
85. Mercé J., Ferras S., Oltra C., et al. Cardiovascular abnormalities in hyperthyroidism: A prospective Doppler echocardiographic study. Am J Med. 2005; 118 (2): 126-131.
86. Metso S., Auvinen A., Salmi J., et al. Increased longterm cardiovascular morbidity among patients treated with radioactive iodine for hyperthyroidism. Clin Endocrinol. 2008; 68(3): 450-457.
87. Miller V., Pearce L., Feinberg W., et al. Differential effect of aspirin versus warfarin on clinical stroke types in patients with atrial fibrillation. Neurology 1996; 46: 238-240.
88. Moruzzi P., Doria E., Agostoni P.G. Medium-term effectiveness of L-thyroxine treatment in idiopathic dilated cardiomyopathy. Am J Med 1996; 101 461-467.
89. Nakazawa H.K., Sakurai K., Hamada N., et al. Management of atrial fibrillation in the post-thyrotoxic state. Am J Med 1982; 72: 903-6.
90. Nakasawa H., Lythall D.A., Noh J., et al. Is there a place for the late cardioversion of atrial fibrillation? A long-term follow-up study of patients with post-thyrotoxic atrial fibrillation. Eur Heart J 2000; 21: 327.
91. Newman C.M., Price A., Davies D.W., et al. Amiodarone and the thyroid: a practical guide to the management of thyroid dysfunction induced by amiodarone therapy. Heart. 1998; 79(2): 121-7.
92. Ojamaa K., Ascheim D., Hryniewicz K., et al. Thyroid hormone therapy of cardiovascular desiase. Cardiovasc Rev Rep 2002; 23: 20.
93. Osman F., Daykin J., Sheppard M., et al. Cardiac rhythm abnormalities in thyrotoxicosis—the explanation for excess vascular mortality. J Endocrinol 2000; 164: 321.
94. Osman F., Franklyn J.A., Sheppard M.C., Gammage M.D. Successful treatment of amiodarone induced thyrotoxicosis. Circulation 2002; 105: 1275-81.
95. Osman F., Gammage M.D., Sheppard M.C., Franklyn J.A. Cardiac dysrhythmias and thyroid dysfunction: the hidden menace? J. Clin. Endocrinol. Metab. 2002; 87: 963-967.
96. Ostrander L.D. Jr., Brandt R.L., Kjelsberg M.O., Epstein FH. Electrocardiographic findings among the adult population of a total natural community, Tecumesh, Michigan. Circulation. 1965; 31: 888-898.
97. Papini E., Petrucci L., Guglielmi R., et al. Long-term changes in nodular goiter: a 5-year prospective randomized trial of levothyroxine suppressive therapy for benign cold thyroid nodules. J Clin Endocrinol Metab 1998; 83: 780-783.
98. Parle J.V., Maisonneuve P., Sheppard M.C., et al. Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lanset 2001; 358: 861.
99. Parmar M.S. Thyrotoxic Atrial Fibrillation. Medscape General Medicine 2005; 7(1): 74.
100. Pearce E.N., Braverman L.E. Clinical use of TSH suppression: why, when, and how? Hot thyroidology 2005; 1 (www.hotthyroidology.com).
101. Perez Parras M.A., Marin Paton M., Negrillo Cantero A.M., et al. Amiodarone-induced hyperthyroidism. An Esp Pediatr 2000; 53 (4): 377-9.
102. Petersen P., Hansen J.M. Stroke in thyrotoxicosis with atrial fibrillation. Stroke 1988; 19: 15-8.
103. Presti C., Hart R. Thyrotoxicosis, atrial fibrillation, and embolism, revisited. Am Heart J 1989; 117: 976-977.
104. Porsche R., Brenner Z.R. Amiodarone-induced thyroid dysfunction. Critical care nurse. 2006; 26 (3): 34-42.
105. Rajeswaran C., Shelton R.J., Gilbey S.G. Management of amiodarone-induced thyrotoxicosis. Swiss Med Wkly 2003; 133: 579-585.
106. Roffi M., Cattaneo F., Brandle M. Thyrotoxicosis and the cardiovascular system. Minerva Endocrinol 2005; 30: 47-58.
107. Roti E., Uberti E.D. Iodine Excess and Hyperthyroidism. Thyroid 2001; 11(5): 493-500.
108. Sandhu R.S., Davies P.H. Amiodarone induced thyroid dysfunction: pathophysiology, diagnosis and management. AdverseDrug React Toxicol Rev 2001; 20: 105-116.
109. Sawin C.T., Geller A., Wolf P., et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 1994; 331: 1249-1252.
110. Sawin C.T. Subclinical hyperthyroidism and atrial fibrillation. Thyroid 2002; 12: 501.
111. Shimizu T., Koide S., Noh J.Y., et al. Hyperthyroidism and the Management of Atrial Fibrillation. Thyroid 2002; 12(6): 489-493.
112. Shreier D.K., Burman K.D. Subclinical Hyperthyroidism: Controversies in Management. Am Fam Physician 2002; 65: 431-8.
113. Squizzato A., Gerdes V.E.A., Brandjes D.P.M., et al. Thyroid Diseases and Cerebrovascular Disease. Stroke 2005; 36: 2302-2310.
114. Surks M.I., Ortiz E., Daniels G.H., et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMAВ 2004; 291(2): 228-38.
115. Tajtakova M., Langer P., Semanova Z., Tomkova Z. Contribution of Thyroid Gland Ultrasound for Screening of Patients with Suspected Subclinical Thyroid Gland Disorders. Bratisl Lek Listy 1999; 100 (4): 196-199.
116. Takasugi H., Ao K., Sato T., et al. Atrial Fibrillation with Hyperthyroidism in a 14-Year-Old Male. Pediatr Cardiol 2006; 27: 772-774.
117. Tan G.H., Gharib H., Reading C.C. Solitary thyroid nodule. Arch Intern Med 1995; 155: 2418-2423.
118. Tenerz A., Forberg R., Jansson R. Is a more active attitude war-ranted in patients with subclinical thyrotoxicosis? Journal of Internal Medicine 1999; 228: 229-233.
119. Thorne S.A., Barnes I., Cullinan P., Somerville J. Amiodarone-associated thyroid dysfunction: risk factors in adults with congenital heart disease. Circulation 1999; 100: 149-154.
120. Toft A.D., Boon N.A. Thyroid disease and the heart. Heart 2000; 84: 455-460.
121. Toft A.D. Clinical practice. Subclinical hyperthyroidism. N Engl J Med 2001; 345: 512-516.
122. Toft A.D. Thyroid hormone treatment, how and when? Thyroid International 2001; 4: 16-18.
123. Topliss D.J., Eastman C.J. Diagnosis and management of hyperthyroidism and hypothyroidism. MJA 2004; 180(4): 186-193.
124. Trip M.D., Wiersinga W.M., Plomp T.A. Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism. Am J Med 1991; 91: 507-511.
125. Trivalle C., Doucet J., Chassagne P., et al. Differences in the signs and symptoms of hyperthyroidism in older and younger patients. J Am Geriatr Soc 1996; 44: 50-53.
126. Vergara P., Picardi G., Nigro G., et al. Evaluation of thyroid dysfunction in patients with paroxysmal atrial fibrillation. Anadolu Kardiyol Derg 2007; 7 (1): 104-106.
127. Villar H.C.C.E., Saconato H., Valente O., Atallah A.N. Thyroid hormone replacement for subclinical hypothyroidism. Cochrane Database of Systematic Reviews 2007, Issue 3. Art. No.: CD003419. DOI: 10.1002/14651858.CD003419.pub2.
128. Wartofsky L. Treatment options for hyperthyroidism. Hosp Pract (Off Ed) 1996; 31: 69-73,76-78, 81-84.
129. Woeber K.A. Update of management of hyperthyroidism and hypothyroidism. Arch Fam Med 2000; 9: 743-747.
130. Zelmanovitz F., Genro S., Gross J.L. Suppressive therapy with levothyroxine for solitary thyroid nodules: a double-blind controlled clinical study and cumulative meta-analyses. J Clin Endocrinol Metab 1998; 83: 3881-3885.
131. Zimetbaum P., Ho K.K.L., Olshansky B., et al. Variation in the Utilization of Antiarrhythmic Drugs in Patients With New-Onset Atrial Fibrillation. Am J Cardiol 2003; 91(1): 81-83.
132. WHO, Unicef, ICCIDD. Assessment of the Iodine Deficiency Disorders and monitoring their elimination. WHO publ.WHO/NHD/01.1, 1-107. 2001. Geneve.